Skip to main content
Clinical Trials/IRCT20200922048804N1
IRCT20200922048804N1
Completed
未知

Inflammation control in patients with COVID-19 using melatonin supplement compare to controls referred to Imam Khomani Hospital

Tehran University of Medical Sciences0 sites20 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
20
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • mild to moderate patients with COVID\-19 who receive Hydroxy chloroquine
  • Confirmation of the disease is based on CT scan and clinical symptoms and physician diagnosis
  • Patients 25\-65 years

Exclusion Criteria

  • Patient with depression, COPD, sleep apnea and seizure
  • Patients with severe kidney problem (eGFR\<30 ml/min)
  • Patients with severe liver problem
  • Patients who receive fluvoxamine, benzodiazepine or zolpidem
  • patients who receive drugs that extends QT
  • Pregnant and breastfeeding mothers
  • Patients who have allergy to melatonin

Outcomes

Primary Outcomes

Not specified

Similar Trials